Synopsys Selling Software Integrity Group to Clearlake Capital, Francisco Partners
By Chris Wack
Synopsys is selling its Software Integrity Group business to Clearlake Capital Group and Francisco Partners in a transaction with a total value of up to $2.1 billion.
The transaction price includes up to $475 million in cash payable upon Francisco Partners and Clearlake achieving a specified rate of return in connection with one or more liquidity transactions.
The company said $1.5 billion will be payable at closing, with $125 million payable in five equal installments after the 75th day following the closing.
The existing Software Integrity Group management team is expected to lead the newly independent, privately held company after the transaction closes. The name of the new standalone entity will be announced at a later date.
The transaction is currently expected to close in the second half of 2024.
In January, Synopsys said it was buying Ansys in a $35 billion cash-and-stock deal, expected to close in the first half of 2025.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 06, 2024 09:43 ET (13:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks